Akt Specific Substrate Peptide, Akt/PKB
CAS No. 276680-69-4
Akt Specific Substrate Peptide, Akt/PKB( ——— )
Catalog No. M41666 CAS No. 276680-69-4
Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 718 | Get Quote |
|
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAkt Specific Substrate Peptide, Akt/PKB
-
NoteResearch use only, not for human use.
-
Brief DescriptionAkt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.
-
Descriptionsubstrate for Akt/PKB
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number276680-69-4
-
Formula Weight817.94
-
Molecular FormulaC36H59N13O9
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
N'-Methylnicotinamid...
N-methylnicotinamide is a metabolite of niacin (or nicotinamide) and is commonly found in human urine. However low levels of urinary excretion of N-methylnicotinamide indicates niacin deficiency. In patients with liver cirrhosis nicotinamide methylation is increased leading to a rise in urinary N-methylnicotinamide. N-methylnicotinamide has been found to be a microbial metabolite.
-
Docosanedioic acid?
BEHENIC ACID is a alkyl-chain-based PROTAC linker. BEHENIC ACID is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
-
Flavanomarein
Flavanomarein demonstrates potent antioxidative property, including free radical scavenging activity, inhibition of lipid peroxidation, as well as lipid-lowering effects in human HepG2 hepatocellular carcinoma cells treated with free fatty acids (FFAs).
Cart
sales@molnova.com